AJAlberto Jaramillo-Jimenez

Alberto Jaramillo-Jimenez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alberto Jaramillo-Jimenez has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • Dag Aarsland

    Centre for Age‐related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway

    11 shared publications
  • Francisco Lopera

    Grupo de Neurociencias de Antioquia, Universidad de Antioquia, Medellín, Colombia

    7 shared publications
  • Miguel Germán Borda

    Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway; Faculty of Health Sciences, University of Stavanger, Stavanger, Norway; Semillero de Neurociencias y Envejecimiento, Ageing Institute, Medical School, Pontificia Universidad Javeriana, Bogotá, Colombia

    7 shared publications
  • Diego Alejandro Tovar-Rios

    Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway

    6 shared publications
  • Dag Aarsland

    Centre for Age-Related Medicine (SESAM), Stavanger University Hospital, Stavanger, Norway

    5 shared publications
  • David Aguillon

    Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

    5 shared publications

Latest Publications

  • Open Access

    Mega‐Analysis of Oscillatory and Aperiodic Resting‐State EEG Alterations in Neurodegenerative Diseases

    by Alberto Jaramillo‐Jimenez, Yorguin Jose Mantilla‐Ramos, Diego Tovar, Francisco Lopera, David Fernando Aguillón Niño, John Fredy Ochoa Gómez, Claire Paquet, Sinead Gaubert, Matteo Pardini, Dario Arnaldi, et al.

    Background: Resting‐state EEG (rsEEG) alterations in the posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs). However, spectral analysis often overlooks the rsEEG non‐rhythmic (aperiodic) component. Studies assessing the oscillatory and aperiodic activity are scarce and frequently underpowered. While multicenter data pooling (mega‐analysis) can enhance statistical power, it may introduce site‐related differences (batch effects). This mega‐analysis differentiates rsEEG oscillatory and aperiodic alterations across NDDs while mitigating batch effects. Method: RsEEGs from 1750 subjects across 12 sites were preprocessed. We pooled signals from healthy controls (HC = 583), Parkinson's Disease (PD = 131), Lewy Body Dementias (LBD = 96), Alzheimer's Disease (AD = 403), Frontotemporal Dementia (FTD = 36), Mild Cognitive Impairment (MCI) in Lewy Bodies pathology or PD (MCI‐LBD = 34), MCI in AD spectrum (MCI‐AD = 245), and Vascular Dementia (VD = 222); Figure 1A. Batch effects harmonization of the posterior power spectrum was performed with reComBat (age and diagnosis‐adjusted). We evaluated harmonization through functional and mass‐univariate permutation ANOVAs. Oscillatory and aperiodic parameters were extracted from the harmonized spectrum with specparam. Group differences across NDDs were estimated with bootstrap pairwise comparisons, mass‐univariate permutation tests, and logistic regression models (age‐adjusted). Result: Visualizations and statistical testing supported reduced batch effects after harmonization; Figure 1B and 1C. As consistent results in the unharmonized and harmonized data, steeper aperiodic parameters and lower oscillatory center frequency characterized LBD compared to all other groups. Besides, oscillatory extended alpha power was lower in AD than in HC and PD; Figure 2. Harmonized oscillatory center frequency and aperiodic parameters improved the separation of LBD compared to unharmonized parameters; Figure 3. Conclusion: Harmonization mitigates batch effects in the rsEEG posterior power spectrum. LBD is characterized by pronounced oscillatory frequency slowing and increased aperiodic activity, while AD displays both oscillatory and aperiodic abnormalities with smaller effect sizes.

  • Open Access

    Characterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study

    by Alberto Jaramillo-Jimenez, Yorguin-Jose Mantilla-Ramos, Diego A. Tovar-Rios, Francisco Lopera, David Aguillón, John Fredy Ochoa-Gomez, Claire Paquet, Sinead Gaubert, Matteo Pardini, Dario Arnaldi, et al.


  • Open Access

    Quantitative electroencephalography in the diagnosis of dementia with Lewy bodies

    by Abhimanyu Mahajan, Alberto Jaramillo-Jimenez, Anita D’aNselmo, Giulia Prete, Lucrezia Bristot, Sara Varanese, Alberto Di Domenico, Nicola Mammarella, Luca Tommasi, Michele Tinazzi, et al.


  • Open Access

    Characterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study

    by Alberto Jaramillo-Jimenez, Yorguin-Jose Mantilla-Ramos, Diego A Tovar-Rios, Francisco Lopera, David Aguillón, John Fredy Ochoa-Gomez, Claire Paquet, Sinead Gaubert, Matteo Pardini, Dario Arnaldi, et al.

    Background Abnormalities in resting-state electroencephalogram (rsEEG) posterior alpha rhythm are promising biomarkers of neurodegenerative diseases (NDDs), often assessed via spectral analysis, ignoring the signal’s non-rhythmic (aperiodic) component. Evidence assessing aperiodic and oscillatory rsEEG abnormalities across NDDs is scarce and often underpowered. Multicenter studies could tackle these limitations, but data pooling might introduce site-related rsEEG differences (batch effects). This study aims to characterize rsEEG oscillatory and aperiodic patterns across NDDs, minimizing potential batch effects. Methods RsEEGs (n = 639; 11 sites) were automatically preprocessed. Signals comprised healthy controls (HC = 153), Lewy Body Dementias (LBD = 95), Parkinson’s Disease (PD = 71), Alzheimer’s Disease (AD = 186), Frontotemporal Dementia (FTD = 23), Mild Cognitive Impairment (MCI) in positive Lewy Body pathology or PD (MCI-LBD = 34), and MCI in positive AD pathology (MCI-AD = 77). Power spectrum batch effects were harmonized using reComBat (age, sex, and diagnosis-adjusted). Harmonization was evaluated with functional and mass-univariate ANOVAs. Oscillatory and aperiodic parameters were extracted from the batch-harmonized power spectrum. NDDs-related differences were estimated with functional and mass-univariate tests, bootstrapped pairwise comparisons, and logistic regressions. Results Qualitative visualizations and statistical testing showed reduced batch effects after harmonization. Statistically significant findings included steeper aperiodic parameters and lower oscillatory center frequency in LBD compared to other NDDs. Additionally, oscillatory extended alpha power was lower in AD vs. LBD. Conclusions Batch effects in the rsEEG power spectrum can be mitigated with harmonization. Oscillatory alpha power reduction may better reflect AD abnormalities, whereas pronounced oscillatory frequency slowing and greater aperiodic activity characterize LBD.

  • Open Access

    ComBat models for harmonization of resting-state EEG features in multisite studies

    by Alberto Jaramillo-Jimenez, Diego A Tovar-Rios, Yorguin-Jose Mantilla-Ramos, John-Fredy Ochoa-Gomez, Laura Bonanni, Kolbjørn Brønnick


  • Open Access

    Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

    by Kathryn A. Wyman-Chick, Parichita Chaudhury, Ece Bayram, Carla Abdelnour, Elie Matar, Shannon Y. Chiu, Daniel Ferreira, Calum A. Hamilton, Paul C. Donaghy, Federico Rodriguez-Porcel, et al.

    This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer’s disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)—parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of pDLB include severe neuroleptic sensitivity, as well as autonomic and neuropsychiatric symptoms. The neuropsychological profile in mild cognitive impairment attributable to Lewy body pathology (MCI-LB) tends to include impairment in visuospatial skills and executive functioning, distinguishing it from MCI due to AD, which typically presents with impairment in memory. pDLB may present with cognitive impairment, psychiatric symptoms, and/or recurrent episodes of delirium, indicating that it is not necessarily synonymous with MCI-LB. Imaging, fluid and other biomarkers may play a crucial role in differentiating pDLB from pAD. The current MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon emission computed tomography (SPECT), loss of REM atonia on polysomnography, and sympathetic cardiac denervation using meta-iodobenzylguanidine SPECT as indicative biomarkers with slowing of dominant frequency on EEG among others as supportive biomarkers. This review also highlights the emergence of fluid and skin-based biomarkers. There is little research evidence for the treatment of pDLB, but pharmacological and non-pharmacological treatments for DLB may be discussed with patients. Non-pharmacological interventions such as diet, exercise, and cognitive stimulation may provide benefit, while evaluation and management of contributing factors like medications and sleep disturbances are vital. There is a need to expand research across diverse patient populations to address existing disparities in clinical trial participation. In conclusion, an early and accurate diagnosis of pDLB or pAD presents an opportunity for tailored interventions, improved healthcare outcomes, and enhanced quality of life for patients and care partners.


  • Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment

    by Alberto Jaramillo-Jimenez, Yamile Bocanegra, Omar Buriticá, David Antonio Pineda Salazar, Leonardo Moreno Gómez, Carlos Andrés Tobón Quintero, Daniel Camilo Aguirre-Acevedo, Melissa Sierra Castrillon, Daniel Vasquez, Juan Esteban Velez-Hernandez, et al.


  • Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment

    by Alberto Jaramillo-Jimenez, Yamile Bocanegra, Omar Buriticá, David Antonio Pineda Salazar, Leonardo Moreno Gómez, Carlos Andrés Tobón Quintero, Daniel Camilo Aguirre-Acevedo, Melissa Sierra Castrillon, Daniel Vasquez, Juan Esteban Velez-Hernandez, et al.


  • Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer's disease: Network analysis and cognitive prognosis

    by Alberto Jaramillo-Jimenez, Lasse M. Giil, Miguel Germán Borda, Diego A. Tovar-Rios, Kåre Andre Kristiansen, Per Bruheim, Dag Aarsland, George E. Barreto, Rolf Kristian Berge


  • Open Access

    Spectral features of resting-state EEG in Parkinson's Disease: A multicenter study using functional data analysis

    by Alberto Jaramillo-Jimenez, Diego A. Tovar-Rios, Johann Alexis Ospina, Yorguin-Jose Mantilla-Ramos, Daniel Loaiza-López, Verónica Henao Isaza, Luisa María Zapata Saldarriaga, Valeria Cadavid Castro, Jazmin Ximena Suarez-Revelo, Yamile Bocanegra, et al.